Lilly breakthrough: Dual treatment clears skin & cuts weight in psoriasis patients
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares
Subscribe To Our Newsletter & Stay Updated